# HighCape Partners

> HighCape Partners is a VC fund backing Health Care and Biotechnology. See 17 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Baltimore, United States
- Total investments: 17
- Last investment: Oct 2023
- Lead investor: 35%
- Fund size: $80M
- Last fund: Sep 2015
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/highcape-partners/about/
- Website: http://highcape.com/

HighCape Partners is a VC fund in Baltimore focused on Health Care and Biotechnology. A growth equity firm that invests in companies that are commercializing high-margin life sciences products.

## Contacts

5 contacts available for HighCape Partners. Shizune tracks 7 team members at HighCape Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/highcape-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 35% |
| Biotechnology | 5 | 29% |
| Medical Device | 4 | 24% |
| Medical | 3 | 18% |
| Fitness | 2 | 12% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 18% |
| Series C | 3 | 18% |
| Seed | 1 | 6% |
| Pre-Seed | 1 | 6% |
| Series A | 1 | 6% |

9 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Dean Tozer | Partner | 0 | — |
| Jennifer Barretta | Partner | 0 | — |
| Kevin Rakin | Founder and Partner | 2 | — |
| Carol Reed | Operating Partner | 0 | — |
| Charles Hart | Operating Partner | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Modifi Bio | Modifi Biosciences is a direct DNA modification developing novel cancer therapeutics. The company's strategy for combating cancer centers around modifying tumor DNA in a way that renders cancer cells irreparable while preserving the integrity of healthy cells. This unique approach empowers researchers to disrupt traditional oncology drugdevelopment methods. | $4.3M | Seed | Oct 16, 2023 |  |
| Elutia | Aziyo is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. From our proprietary tissue processing platforms, we have developed a portfolio of advanced regenerativemedical products that are designed to be very similar to natural biological material. | $10.5M | Post-IPO Equity | Sep 19, 2023 |  |
| Modifi Bio | Modifi Biosciences is a direct DNA modification developing novel cancer therapeutics. The company's strategy for combating cancer centers around modifying tumor DNA in a way that renders cancer cells irreparable while preserving the integrity of healthy cells. This unique approach empowers researchers to disrupt traditional oncology drugdevelopment methods. | $6.4M | Seed | Jul 28, 2022 |  |
| Wellinks | Wellinks (previously Convexity Scientific) is a New Haven Connecticut based digital health company focused on innovations to reinvent respiratory care around the people who need it. The company began as Convexity Scientific, launching a FDA cleared portable nebulizer, Flyp, to the market in 2018. In transforming to Wellinks, Convexity Scientificacquired an early stage startup in the connected medical device and digital health field. Merging the teams and moving forward under the Wellinks brand, the combined company has created a digital health solution for chronic respiratory disease management that incorporates a suite of connected medical devices and software to enable optimized medication adherence, symptom tracking, diagnostic monitoring, and personalized coaching. | $25M | Series C | Nov 03, 2021 |  |
| Wellinks (formerly Convexity Scientific) | Wellinks is a COPD disease management organization that provides clients with individualized treatment and assistance to help them manage their condition successfully. They focus on each member's individual needs to create a clear route to better health. | $25M | Series C | Nov 03, 2021 |  |
| Alphina Therapeutics | Alphina Therapeutics is a biotechnology company that aims to leverage proprietary biomarkers and breakthrough insights for cancer patients. Its focus is on leveraging the synthetic lethal context of certain cancer patient subsets that have NAD Metabolic Deficiencies (NMD) through the development of companion diagnostics. Their goal is to developbest-in-class targeted therapies against the NAD pathway nodes in patients whose cancers exhibit hallmarks of NMD and rapidly translate these into the clinic. | $40M | Series A | Sep 09, 2021 |  |
| Cybrexa Therapeutics | Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Our approach will change the paradigm of drug delivery, and itwill greatly enhance the therapeutic index. It has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of tumor-localizing DNA repair inhibitors can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy. | $40.2M | Series B | Mar 10, 2021 |  |
| Alphina Therapeutics | Alphina Therapeutics is a biotechnology company that aims to leverage proprietary biomarkers and breakthrough insights for cancer patients. Its focus is on leveraging the synthetic lethal context of certain cancer patient subsets that have NAD Metabolic Deficiencies (NMD) through the development of companion diagnostics. Their goal is to developbest-in-class targeted therapies against the NAD pathway nodes in patients whose cancers exhibit hallmarks of NMD and rapidly translate these into the clinic. |  | Pre-Seed | Dec 15, 2020 |  |
| Flyp Nebulizer | Flyp Nebulizer, the medical device is reinvented by Weblinks for respiratory care around the people who need it most. It works at ultrasonic speed to create a fine aerosol of medication. Flyp Nebulizer works quickly to deliver treatment within 7-minute average. | $4M | Series B | Sep 27, 2019 |  |
| Wellinks | Wellinks (previously Convexity Scientific) is a New Haven Connecticut based digital health company focused on innovations to reinvent respiratory care around the people who need it. The company began as Convexity Scientific, launching a FDA cleared portable nebulizer, Flyp, to the market in 2018. In transforming to Wellinks, Convexity Scientificacquired an early stage startup in the connected medical device and digital health field. Merging the teams and moving forward under the Wellinks brand, the combined company has created a digital health solution for chronic respiratory disease management that incorporates a suite of connected medical devices and software to enable optimized medication adherence, symptom tracking, diagnostic monitoring, and personalized coaching. | $14M | Series B | Sep 26, 2019 |  |

10 of 17 investments shown.

## Co-investors
- [Connecticut Innovations](https://shizune.co/investors/profile/connecticut-innovations) — VC Fund, 9 deals together
- [Benslie Investment Group](https://shizune.co/investors/profile/benslie-international-ltd) — VC Fund, 4 deals together
- [Stonehenge Capital](https://shizune.co/investors/profile/stonehenge-capital) — VC Fund, 4 deals together
- [MVM Life Science Partners](https://shizune.co/investors/profile/mvm-life-science-partners) — VC Fund, 3 deals together
- [Ironwood Capital](https://shizune.co/investors/profile/ironwood-capital) — VC Fund, 2 deals together
- [5Y Capital](https://shizune.co/investors/profile/morningside-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does HighCape Partners invest in?

HighCape Partners invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series B and Series C stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact HighCape Partners?

Public channels for HighCape Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at HighCape Partners?

The team at HighCape Partners includes Dean Tozer (Partner), Jennifer Barretta (Partner) and Kevin Rakin (Founder and Partner), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co